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Protein Kinase Signaling in 
Keratinocyte Differentiation control
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Proper epidermal keratinocyte differentiation, which is necessary for cutaneous 
barrier function, is altered in many common skin diseases. Keratinocyte 
differentiation is controlled by a complex signaling network involving multiple 
members of the protein kinase c and mitogen-activated protein kinase signaling 
kinases. Using an RnA interference knockdown approach, Adhikary et al. identified 
essential nodes in this signaling network, revealing remarkable kinase specificity.
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Most of us take differentiation of our 
epidermis for granted. Our skin reliably 
provides adequate barrier function and 
the aesthetic appearance associated 
with a normal, healthy skin. For a signif-
icant number of people, however, epi-
dermal differentiation does not proceed 
normally, and their skin is a chronic 
source of irritation, inflammation, and 
aggravation. Several of the most com-
mon skin diseases, including eczema 
(atopic dermatitis), ichthyosis (vul-
garis, lamellar, and X-linked), and pso-
riasis, are associated with fundamental 
defects in epidermal differentiation. 
These defects are not always simply a 
response to an underlying disease pro-
cesses; often they are pathogenic. For 
example, ichthyosis vulgaris and atopic 
dermatitis are linked to loss-of-function 
mutations in the intermediate filament 
bundling protein filaggrin (Smith et al., 
2006; Palmer et al., 2006). Because 
disruption of epidermal differentiation 
is responsible for a considerable por-
tion of the morbidity associated with 
these diseases, a better understand-
ing of the basic processes that control 
keratinocyte differentiation is needed to 
achieve pharmacological improvement 
for the tens of millions of people who 
suffer from them.
Adhikary et al. (2010, this issue) 
focus on the transcriptional regula-
tion of involucrin, a constituent of the 
cornified envelope and resident of the 
epidermal differentiation complex 
on chromosome 1q21. Involucrin is 
expressed in the spinous and granu-
lar layers of the epidermis and is tran-
scriptionally upregulated by a variety 
of differentiating agents, e.g., calcium, 
12-O-tetradecanoylphorbol-13-acetate 
(TPA), vitamin D, and (−)-epigallocate-
chin-3-gallate (EGCG). Although invo-
lucrin-null mice appear normal and 
have no obvious skin phenotype (Djian 
et al., 2000), involucrin induction is 
part of the coordinated transcriptional 
response during keratinocyte differ-
entiation, and it can be considered 
a prototypical keratinocyte differen-
tiation marker that shares regulatory 
overlap with many genes residing in 
the epidermal differentiation complex. 
Thus, involucrin is a reasonable surro-
gate for keratinocyte differentiation. In 
addition, several of the critical signal-
ing kinases identified as important for 
involucrin induction are also important 
for morphological changes that accom-
pany differentiation.
The findings of Adhikary et al. (2010) 
help delineate a signaling network 
involving protein kinase C (PKC)-δ, 
MEKK-1, MEK-3, MEK-6, and p38-δ as 
essential to activate activating protein 
1 nuclear translocation, DNA binding, 
and involucrin gene expression by mul-
tiple differentiation stimuli (Figure 1). 
PKC-η is also implicated in involucrin 
induction by TPA, but not Ca2+ or EGCG. 
PKC isoforms can activate mito-
gen-activated protein kinase (MAPK) 
pathways via multiple mechanisms, 
and overexpression of both PKC-δ and 
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PKC-η has previously been shown to 
activate p38-δ (Efimova et al., 2002). It 
is noteworthy that only specific mem-
bers of the PKC and MAPK pathways 
are required for involucrin induction, 
and the issue of signaling specificity is 
highlighted in this Commentary.
PKc specificity
Activation of the PKC family of serine/
threonine kinases, by multiple agonists, 
is a potent inducer of keratinocyte dif-
ferentiation. Although at least five PKC 
isoforms (α, δ, ε, η, and ζ) are expressed 
in the epidermis, Adhikary et al. (2010) 
identified PKC-δ as having the primary 
role in KC differentiation induced by 
TPA, calcium, and EGCG. PKC-δ is 
a member of the Ca2+-independent 
“novel” subclass of PKC isoforms, and 
it is highly expressed in both mouse 
and human epidermis. PKC-δ translo-
cates to the membrane in response to 
extracellular calcium, most likely in 
response to diacylglycerol generated by 
phospholipase C (Denning et al., 1995). 
However, no specific alterations in sub-
cellular localization have been noted in 
differentiating suprabasal keratinocytes 
in vivo (D’Costa et al., 2006). In addi-
tion, there are no major defects in the 
epidermis of PKC-δ-null mice; thus, the 
role of PKC-δ in normal epidermal dif-
ferentiation requires more study. PKC-δ 
has also been strongly linked to apopto-
sis in keratinocytes and other cell types 
in response to genotoxic agents, such 
as UV radiation (Denning et al., 1998). 
Although similarities exist between the 
programmed cell death pathways of 
keratinocyte terminal differentiation 
and apoptosis (destruction of organ-
elles, genetically programmed), many 
notable differences are also evident.
It is uncertain what specifies PKC-δ 
activation leading to a differentiated or 
apoptotic cell fate, but it may be related 
to the magnitude, duration, and loca-
tion of PKC-δ activation. Activation 
of PKC-δ by differentiating agents is 
modest and transient, whereas PKC-δ 
cleavage and activation by genotoxic 
apoptotic agents is substantial and 
sustained. PKC-δ activation mecha-
nisms also differ, with differentiating 
stimuli inducing a transient activation 
of the full-length PKC-δ via agonist 
(diacylglyc erol, TPA) binding to the C1 
domain. In contrast, apoptotic stimuli 
induce proteolytic cleavage of PKC-δ, 
which separates the regulatory domain 
from the catalytic domain to generate a 
constitutively active catalytic fragment 
(Denning et al., 1998). Compared with 
classical agonist-induced activation, 
this cleavage activation mechanism 
results in altered PKC-δ subcellular 
distribution and possibly substrate 
access. PKC scaffold proteins, such 
as the receptors for activated C kinase 
(RACKs), are involved in determining 
PKC isoforms’ functional selectivity by 
restricting substrate access (Churchill 
et al., 2009). RACKs interact with PKC 
isoforms via their C2 domains, and 
these vary in sequence among PKC iso-
forms. Thus, unlike the proteolytic cata-
lytic fragment of PKC-δ, which lacks its 
C2 domain, the full-length PKC-δ acti-
vated by diacylglycerol or TPA should 
be bound to its RACK. Furthermore, 
PKC isoform-selective RACK binding 
may also explain why PKC-δ has a role 
in involucrin induction whereas the 
closely related PKC-ε does not.
PKC-η is also implicated by Adhikary 
et al. (2010) in the induction of involu-
crin promoter activation by TPA. PKC-η 
is unique among PKC isoforms in that 
its expression is restricted largely to 
cells undergoing squamous differentia-










Figure 1. Hypothetical signaling pathway leading to involucrin gene expression. The induction of 
involucrin promoter activation by the PKc agonist TPA involves both PKc-η and PKc-δ, whereas 
induction of involucrin by extracellular ca2+ or eGcG requires PKc-δ predominantly. The activation 
of PKc-δ by ca2+ and eGcG is indirect, as indicated by dotted lines. MeKK-1, MeK-3, MeK-6 and 
p38-δ are each involved in induction of involucrin by TPA. Both MeK-3 and MeK-6 are required 
for involucrin promoter activation, suggesting that they may lie in the same pathway or activate 
each other. These signaling kinases are also required for nuclear localization and DnA-binding 
activity of activating protein 1 (AP1) transcription factors (JunB, JunD, c-fos, and Fra-1). eGcG, 
(−)-epigallocatechin-3-gallate; PKc, protein kinase c; TPA, 12-O-tetradecanoylphorbol-13-acetate.
Clinical Implications
•  Many of the most common skin diseases involve alterations in 
keratinocyte differentiation.
•  Defective keratinocyte differentiation is not only a symptom but also an 
instigator of some dermatoses.
•  Identification of key signaling networks regulating epidermal 
differentiation may permit pharmacological rescue of normal 
keratinocyte differentiation.
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that PKC-η is not required for involucrin 
promoter activation by Ca2+ or EGCG 
supports the idea that individual dif-
ferentiation-inducing agents exhibit 
specific mechanisms of action. The 
requirement for PKC-η in TPA-induced 
involucrin expression is consistent with 
previous findings from the Eckert lab 
showing that overexpression of PKC-η 
can induce involucrin (Efimova et al., 
2002). However, these earlier studies 
found that PKC-ε overexpression also 
induced involucrin, whereas the cur-
rent study clearly shows that PKC-ε is 
not involved in involucrin induction by 
TPA. These conflicting results highlight 
the need for caution when interpret-
ing results from overexpression studies 
and reinforce the importance of loss-
of-function approaches, such as RNA 
interference.
maPK specificity
Although p38-α, -β, and -δ are all 
expressed in keratinocytes, only siRNA 
knockdown of p38-δ inhibits involucrin 
induction. This selectivity for p38-δ 
raises the question of how specific-
ity is conferred on individual compo-
nents of the MAPK signaling pathway. 
MAPK’s signaling modules—consisting 
of MAPK, MAPK kinases, and MAPK 
kinase kinases—are often coordinately 
activated by binding to specific scaf-
folding or adapter proteins. In the case 
of p38 MAPKs, scaffolding proteins 
such as JIP2 and JLP have been identi-
fied, but it is unclear whether they are 
specific for individual p38 isoforms. 
Earlier work by the Eckert lab identi-
fied p38-δ as the only p38 isoform 
activated by several inducers of differ-
entiation (TPA, calcium, okadaic acid), 
and the current RNA interference 
results are consistent with that obser-
vation (Efimova et al., 2002). Thus, 
although it is clear that p38-δ is the 
p38 isoform responsible for involucrin 
induction, the mechanism of this selec-
tivity remains elusive. Earlier studies on 
involucrin gene expression, also by the 
Eckert lab, found an inverse regulation 
between p38-α and p38-δ involving 
MEK-6, and this type of cross-inhibition 
may be another explanation for p38 
isoform functional selectivity (Dashti 
et al., 2001).
The p38 MAPKs can be activated by 
MEK-3/MKK-3 and MEK-6/MKK-6, and 
knockdown of each of these kinases 
significantly reduced involucrin pro-
moter activation. This lack of redun-
dancy suggests that MEK-3 and MEK-6 
are dependent on each other and 
thus may lie in the same pathway or 
stimulate the activation of each other. 
Additional studies looking at activa-
tion of MEK-3 in cells lacking MEK-6, 
and vice versa, are needed to resolve 
this finding.
Pharmacological rescue of 
differentiation
The impact of defective epidermal 
keratinocyte differentiation on human 
health is enormous. For many patients 
with dermatoses involving abnormal 
epidermal differentiation, symptomatic 
relief comes from inhibiting the inflam-
matory response to altered epidermal 
barrier function with topical steroids 
and relieving dryness with moisturiz-
ing creams and oils. Pharmacological 
approaches to restoring normal skin 
homeostasis directly in these patients 
should be more effective and well tol-
erated. Given the numerous examples 
in knockout mice of compensation 
among epidermal differentiation struc-
tural proteins, a more thorough under-
standing of signaling networks that 
regulate genes within the epidermal 
differentiation complex, such as invo-
lucrin, may reveal targets for drugs 
capable of restoring proper epidermal 
keratinocyte differentiation.
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